TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3516258

Group type: EXPERIMENTAL
Intervention: Isoxsuprine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29305397

Group type: EXPERIMENTAL
Intervention: Falls Management Exercise (FaME) programme
Number of subjects: 650
Study: 28186887

Group type: EXPERIMENTAL
Intervention: Randomized Singular Value Decomposition (rSVD)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Randomized Spatial Downsampling
Number of subjects: 2

Group type: COMPARATOR
Intervention: Full Singular Value Decomposition (SVD)
Number of subjects: 2
Study: 25686857

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 72
Study: 23221579

Group type: EXPERIMENTAL
Intervention: 200 mg DHA and 300 mg EPA supplementation for 6 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: 2 mL olive oil/d for 6 months (Control)
Number of subjects: 172
Study: 21722960

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin formulated with 100-mg SNAC (5 mg dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercially available 5-mg cyanocobalamin tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercially available 1-mg cyanocobalamin IV
Number of subjects: 20
Study: 19303160

Group type: EXPERIMENTAL
Intervention: PI-88 (160 mg/day)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: PI-88 (250 mg/day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Untreated (Group A)
Number of subjects: 168
Study: 17040264

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrocortisone butyrate ointment 1%
Number of subjects: 16
Study: 15301646

Group type: EXPERIMENTAL
Intervention: Parenting program
Number of subjects: 157

Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 157
Study: 10931801

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose on day 1, followed by 75 mg/d) plus aspirin (325 mg/d)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d) plus aspirin (325 mg/d)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Ticlopidine (250 mg BID) plus aspirin (325 mg/d)
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: All treatment groups (Clopidogrel and Ticlopidine)
Number of subjects: 1020
Study: 9135351

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% halothane
Number of subjects: 15
Study: 7963711

Group type: EXPERIMENTAL
Intervention: sCD4‐PE40, 1, 5, 10, or 15 micrograms/kg by intravenous bolus once a month for 2 months, then weekly for 6 weeks.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: sCD4‐PE40, 10 micrograms/kg (maximally tolerated dose).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: sCD4‐PE40.
Number of subjects: 24
Study: 3312020

Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amoxicillin with clavulanic acid
Number of subjects: 42
Study: 31900620

Group type: EXPERIMENTAL
Intervention: Positive experience with the oncologist
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Caregivers’ experience with the oncologist
Number of subjects: 204
Study: 30396343

Group type: EXPERIMENTAL
Intervention: Moxibustion therapy with educational video program
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group with only educational program
Number of subjects: 51
Study: 28205278

Group type: EXPERIMENTAL
Intervention: 1.25 μg ramosetron
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: 2.5 μg ramosetron
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: 5 μg ramosetron
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 26378721

Group type: EXPERIMENTAL
Intervention: Psychoeducation emphasizing malleable biology
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychoeducation
Number of subjects: 216

Group type: COMPARATOR
Intervention: Biology-only psychoeducation
Number of subjects: 216
Study: 22674639

Group type: EXPERIMENTAL
Intervention: Vaginal cones (VC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study: 21600550

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 18204339

Group type: EXPERIMENTAL
Intervention: Pindolol 7.5 mg/d
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17063022

Group type: EXPERIMENTAL
Intervention: Xylitol candies
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no xylitol candies)
Number of subjects: 145
Study: 12639650

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interstitial laser coagulation (ILC)
Number of subjects: 72
Study: 11203848

Group type: EXPERIMENTAL
Intervention: F2000/Z100 sandwich restorations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Vitremer/Z100 sandwich restorations
Number of subjects: 72

Group type: COMPARATOR
Intervention: Z100 total-bond restorations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sandwich restorations on contaminated dentin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All types of restorations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acid etching of the dentin
Number of subjects: 72
Study: 9347195

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 8126146

Group type: COMPARATOR
Intervention: Nal-Glu alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nal-Glu + T 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nal-Glu + T 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nal-Glu + T + Teslac 250 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2577498

Group type: EXPERIMENTAL
Intervention: High-dose ranitidine (300 mg q.d.s.)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard dose ranitidine (300 mg nocte)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Standard ranitidine therapy
Number of subjects: 245
Study: 175669

Group type: EXPERIMENTAL
Intervention: Split-course radiation therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Continuous radiation therapy
Number of subjects: 188
Study: 31180620

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (Control)
Number of subjects: 18
Study: 27771761

Group type: EXPERIMENTAL
Intervention: Coping skills training for junior gynecologists (12 weekly sessions over 3 months)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 78
Study: 25757039

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (52 weeks)
Number of subjects: 126
Study: 24176893

Group type: EXPERIMENTAL
Intervention: Physical exercise at least once per week for 6 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Regular training group (n = 27)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Irregular training group (n = 33)
Number of subjects: 104
Study: 22769971

Group type: EXPERIMENTAL
Intervention: Well London program (community engagement intervention)
Number of subjects: 5321

Group type: COMPARATOR
Intervention: Control communities (matched neighborhoods)
Number of subjects: 5321
Study: 19382463

Group type: EXPERIMENTAL
Intervention: Tanreqing Injection (20 mL) with 5% G/NS (500 mL) once a day for two weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Yanhuning injection (0.4 g) with 5% G/NS (500 mL) once a day for two weeks
Number of subjects: 87
Study: 17718364

Group type: EXPERIMENTAL
Intervention: Centred egocentric condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allocentric condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decentred egocentric condition
Number of subjects: 0
Study: 15615744

Group type: EXPERIMENTAL
Intervention: Iodide iontophoresis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Iodide application without current
Number of subjects: 28
Study: 11952025

Group type: EXPERIMENTAL
Intervention: Enteric-coated fluoxetine 90 mg on both days (LPWDx2)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo on both days (PLC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Placebo 14 days before menses and enteric-coated fluoxetine 90 mg 7 days before menses (LPWDx1)
Number of subjects: 257
Study: 9812081

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8950297

Group type: EXPERIMENTAL
Intervention: RU486 (mifepristone)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Spironolactone 200mg
Number of subjects: 8
Study: 1771220

Group type: COMPARATOR
Intervention: Glucose 0 g (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose 30 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose 100 g
Number of subjects: 0
Study: 6941444

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g (single oral dose, pre-operatively)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 210
Study: 31402028

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine bathing
Number of subjects: 0
Study: 28061017

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study: 26476610

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 720
Study: 23469080

Group type: EXPERIMENTAL
Intervention: Serum CXCL5 levels
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Prognostic score model (C-C model) based on sCXCL5 levels and clinical classification
Number of subjects: 290
Study: 21789509

Group type: EXPERIMENTAL
Intervention: Single-incision sleeve gastrectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopic sleeve gastrectomy
Number of subjects: 50
Study: 19116328

Group type: EXPERIMENTAL
Intervention: Diet protocol (n = 45)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Exercise protocol (n = 48)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Diet plus exercise protocol (n = 58)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control protocol (n = 36)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 187
Study: 16274980

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg in a single inhaler
Number of subjects: 339

Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg
Number of subjects: 339
Study: 15229417

Group type: EXPERIMENTAL
Intervention: Urgent endoscopy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Elective endoscopy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Outpatient care recommendation
Number of subjects: 93
Study: 11085351

Group type: EXPERIMENTAL
Intervention: Artemisinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 1496226

Group type: EXPERIMENTAL
Intervention: Radiation therapy following lumpectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No radiation therapy following lumpectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic therapy following IBTR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumpectomy with and without breast irradiation
Number of subjects: 0
Study: 6196251

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside monophosphate (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (10 patients)
Number of subjects: 20
Study: 31783827

Group type: EXPERIMENTAL
Intervention: Peer support worker (PSW+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (PSW‐)
Number of subjects: 0
Study: 29565776

Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 30
Study: 26882332

Group type: EXPERIMENTAL
Intervention: Behavioral parent training (8 group sessions) and brief teacher consultation to establish a Daily Report Card
Number of subjects: 146

Group type: COMPARATOR
Intervention: Extended‐release methylphenidate (equivalent to .15 mg/kg/dose bid)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Behavioral parent training
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Initial behavior modification
Number of subjects: 146
Study: 25030943

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly immediately after ERCP
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no diclofenac)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diclofenac group
Number of subjects: 120
Study: 23290323

Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1004
Study: 20927492

Group type: EXPERIMENTAL
Intervention: Combined training (CG)
Number of subjects: 50
Study: 18823986

Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 or 90 mg qd)
Number of subjects: 34701

Group type: COMPARATOR
Intervention: Diclofenac (150 mg qd)
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 34701

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 34701

Group type: COMPARATOR
Intervention: Etoricoxib vs Diclofenac
Number of subjects: 34701
Study: 16505756

Group type: EXPERIMENTAL
Intervention: LV5FU2‐irinotecan
Number of subjects: 134

Group type: COMPARATOR
Intervention: LV5FU2‐cisplatin
Number of subjects: 134

Group type: COMPARATOR
Intervention: LV5FU2 alone
Number of subjects: 134
Study: 12598340

Group type: EXPERIMENTAL
Intervention: S16020 (80 or 100 mg/m2, 3‐h infusion every 3 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methotrexate (40 or 50 mg/m2, bolus injection weekly for a minimum of 6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S16020
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 36
Study: 10583282

Group type: EXPERIMENTAL
Intervention: Laparoscopy during the first 18 hours of admission
Number of subjects: 120

Group type: COMPARATOR
Intervention: Close observation, conventional investigation, and surgical intervention if signs of peritonism developed
Number of subjects: 120
Study: 8739138

Group type: EXPERIMENTAL
Intervention: Local antifungal agent (miconazole, 2% gel) for 4 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Systemic antifungal agent (fluconazole, 50 mg) for 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (new complete dentures)
Number of subjects: 49
Study: 1934940

Group type: EXPERIMENTAL
Intervention: Forced expirations (manoeuvre A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Forced inspirations and slow expirations (manoeuvre B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall mucociliary clearance
Number of subjects: 16
Study: 6240764

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study: 31096012

Group type: EXPERIMENTAL
Intervention: MI‐E (‐50/+50 cmH2O) plus endotracheal suctioning
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MI‐E (‐30/+30 cmH2O) plus endotracheal suctioning
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isolated endotracheal suctioning (IES)
Number of subjects: 16
Study: 30046018

Group type: EXPERIMENTAL
Intervention: Automated phone heat warning system
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Control group (no warning)
Number of subjects: 1328
Study: 26963592

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal diet (ND)
Number of subjects: 24
Study: 25283470

Group type: EXPERIMENTAL
Intervention: Milnacipran (serotonin-norepinephrine reuptake inhibitor)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 23392399

Group type: EXPERIMENTAL
Intervention: hsCRP (high-sensitivity C-reactive protein)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: ICAM-1 (intercellular adhesion molecule 1)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: VCAM-1 (vascular cell adhesion molecule 1)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: TNF-α receptor 1 (tumor necrosis factor α receptor 1)
Number of subjects: 1441
Study: 20927577

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 18171181

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no hand gel)
Number of subjects: 0
Study: 17139600

Group type: EXPERIMENTAL
Intervention: Combination treatment with inhaled iloprost and bosentan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with inhaled iloprost and sildenafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with bosentan and sildenafil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with two or three of the mentioned drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study: 12607159

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 208

Group type: COMPARATOR
Intervention: Routine surgery
Number of subjects: 208
Study: 11070991

Group type: EXPERIMENTAL
Intervention: Preoperative administration of somatostatin analogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (e.g., bromocriptine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study: 8865083

Group type: EXPERIMENTAL
Intervention: Post-eccentric exercise clamp (PEC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control clamp (CC)
Number of subjects: 7
Study: 1641148

Group type: EXPERIMENTAL
Intervention: Soy test meal
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Casein test meal
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both test meals
Number of subjects: 11
Study: 6861871

Group type: EXPERIMENTAL
Intervention: Oral morphine tablets (20-40 mg every 4 to 6 hours)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral morphine solution (20-40 mg every 4 to 6 hours)
Number of subjects: 7
Study: 31497864

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study: 30501629

Group type: EXPERIMENTAL
Intervention: In-clinic physical therapy focused on strengthening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-clinic physical therapy containing placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocolized home exercise programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or standard care)
Number of subjects: 0
Study: 26770048

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 60
Study: 25264782

Group type: EXPERIMENTAL
Intervention: Biojector IM injection of rAd5 vaccine at 10^10 PU
Number of subjects: 31

Group type: COMPARATOR
Intervention: Needle injection of rAd5 vaccine at 10^10 PU
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Booster dose of rAd5 vaccine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Biojector delivery of rAd5 vaccine
Number of subjects: 31
Study: 22419732

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg plus pioglitazone (any dose)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg plus pioglitazone (any dose)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Pioglitazone alone (Pio alone)
Number of subjects: 1554
Study: 20595675

Group type: EXPERIMENTAL
Intervention: Causative Classification System (CCS)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: ASCO grade 1
Number of subjects: 381

Group type: COMPARATOR
Intervention: TOAST
Number of subjects: 381
Study: 17331805

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 51
Study: 16359548

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study: 12445410

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9872708

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 106

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Completion of both short-term and maintenance phases
Number of subjects: 106
Study: 7608860

Group type: EXPERIMENTAL
Intervention: Intoxicated participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 0
Study: 2392794

Group type: EXPERIMENTAL
Intervention: Transcricoid injection of 100 mg lignocaine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Spray as you go technique with 240 mg lignocaine
Number of subjects: 62
Study: 373777

Group type: EXPERIMENTAL
Intervention: Ambroxol 45 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromhexine 36 mg/d
Number of subjects: 30
Study: 31915906

Group type: EXPERIMENTAL
Intervention: 4-HIIT (4×4 min bouts at 85-95% HR peak, 3×/week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MCT (30 min at 60-70% HR peak, 5×/week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1-HIIT (1×4 min bout at 85-95% HR peak, 3×/week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Interaction genotypes (H1, H2, H3, H4)
Number of subjects: 70
Study: 31416746

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72